CAR-T (Autoimmune) vs CAR-Treg — Immunology Deal Terms Comparison
Market Analysis
In immunology, CAR-T (Autoimmune) and CAR-Treg represent two of the most actively transacted modalities. At Phase 2, CAR-T (Autoimmune) deals carry a median total deal value of $5.0B with $914M upfront, compared to $4.2B total value and $767M upfront for CAR-Treg. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. CAR-T (Autoimmune) development milestones average $820M versus $688M for CAR-Treg. Commercial milestones are $1.8B for CAR-T (Autoimmune) and $1.5B for CAR-Treg. Royalty rates range from 16.3%-27.2% for CAR-T (Autoimmune) and 15.5%-25.8% for CAR-Treg.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do CAR-T (Autoimmune) and CAR-Treg deal terms compare in immunology?
Which modality commands higher royalty rates: CAR-T (Autoimmune) or CAR-Treg?
How do milestone structures differ between CAR-T (Autoimmune) and CAR-Treg?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.